Xpress Genomics

Executive Summary

Xpress Genomics is a Swedish biotechnology company founded in 2022 that provides next-generation sequencing (NGS) and omics services, with a core focus on scalable, full-length single-cell RNA-sequencing (scRNA-seq). The company has expanded its portfolio to include bulk RNA-seq, spatial transcriptomics, ATAC-seq, and DNA-seq, leveraging an in-house automation platform to deliver high-quality genomic data with rapid turnaround times. Positioned in the growing genomics services market, Xpress Genomics targets academic and pharmaceutical researchers seeking cost-effective, fast, and reliable sequencing solutions. Despite being a relatively new entrant, Xpress Genomics differentiates itself through its automation-driven efficiency and comprehensive service menu. The company operates in Stockholm, Sweden, and is privately held with no disclosed funding or valuation. Key growth drivers include increasing demand for single-cell and spatial genomics in drug discovery and personalized medicine, as well as potential partnerships with larger biotech firms. However, the company faces competition from established players and must scale its operations to capture market share. Its success hinges on continued technological innovation, client acquisition, and securing additional capital to support expansion.

Upcoming Catalysts (preview)

• Q3 2026Scaling automation platform to increase throughput70% success
• Q4 2026Strategic partnership with major pharma for single-cell services50% success
• Q1 2027Launch of multi-omics integration service60% success